0001679082-22-000009.txt : 20220110 0001679082-22-000009.hdr.sgml : 20220110 20220110090155 ACCESSION NUMBER: 0001679082-22-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220110 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 22519961 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 207-400-3351 MAIL ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB 8-K 1 myov-20220110.htm 8-K myov-20220110
false000167908200016790822022-01-102022-01-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 10, 2022

Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
 001-37929 
 (Commission File No.) 
Bermuda 98-1343578
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
Suite 1, 3rd Floor 
11-12 St. James’s Square
London
SW1Y 4LB
United KingdomNot Applicable
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: +44 207 400 3351
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Shares, par value $0.000017727 per shareMYOVNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.
On January 10, 2022, Myovant Sciences Ltd. (“Myovant”) issued a press release announcing its preliminary unaudited financial results for the fiscal quarter ended December 31, 2021, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The preliminary unaudited financial results contained in the press release do not present all information for an understanding of Myovant’s financial condition as of December 31, 2021 and its results of operations for the fiscal quarter ended December 31, 2021. The review of Myovant’s financial statements for the fiscal quarter ended December 31, 2021 is ongoing and could result in changes to the information in the press release.

In accordance with General Instruction B.2. of Form 8-K, the information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, or to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any of Myovant’s filings under the Exchange Act or the Securities Act, except as expressly set forth by specific reference in such a filing.

Item 9.01   Financial Statements and Exhibits.
Exhibit Index
Exhibit No. Description
   
 
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation Linkbase
101.DEFXBRL Taxonomy Extension Definition Linkbase
101.LABXBRL Taxonomy Extension Label Linkbase
101.PREXBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File - Formatted as Inline XBRL and contained in Exhibit 101


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 Myovant Sciences Ltd.
  
Date: January 10, 2022By:
/s/ Uneek Mehra
 Name:Uneek Mehra
  Title:Principal Financial Officer
   




 EX-99.1 2 a01102022myovantprx010422e.htm EX-99.1 Document

Exhibit 99.1



myovant16a.jpg

Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

•Estimated total revenue of $54.0-$55.0 million, including net product revenue of $28.8-$29.8 million
•Estimated ORGOVYX® net product revenue of $24.2-$24.6 million, reflecting 40% sequential volume growth compared to fiscal second quarter 2021, partially offset by a lower net price
•Estimated MYFEMBREE® net product revenue of $2.3-$2.6 million; New-to-brand prescription (NBRx) share among GnRH antagonist therapies FDA-approved for the treatment of uterine fibroids grew to 45% in December 2021, six months following launch
•Myovant remains well-capitalized with cash, cash equivalents and marketable securities of approximately $527.8 million as of December 31, 2021
•Myovant to present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time

BASEL, Switzerland, January 10, 2022 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial results for the third quarter of fiscal year 2021. The financial information presented in this press release may be adjusted at a later date following the completion of customary quarterly financial reviews and audit procedures.

“Myovant delivered on its mission of redefining care for women and for men over the course of calendar-year 2021 as momentum for ORGOVYX and MYFEMBREE launches continued to build, positioning the company for long-term success. Our strong quarterly performance continues to give us the confidence that ORGOVYX and MYFEMBREE have the potential to become standard of care therapies in advanced prostate cancer and uterine fibroids, respectively,” said David Marek, Chief Executive Officer of Myovant Sciences, Inc. “We believe we have set the stage for an important year in 2022 as we seek to drive significant revenue growth with continued ORGOVYX adoption and the potential launch of MYFEMBREE in endometriosis, pending FDA approval, while also expanding our pipeline by advancing relugolix lifecycle opportunities and pursuing business development.”

Unaudited preliminary revenue results:

Total revenue for the three months ended December 31, 2021 is estimated to be in the range of $54.0-$55.0 million. There was $1.4 million of total revenue recorded in the three months ended December 31, 2020. Estimated total revenue consisted of the following:

•Net product revenue is estimated to be in the range of $28.8-$29.8 million in fiscal third quarter 2021. There was no such revenue recorded in the comparable prior year period. Estimated net product revenue consists of the following:
◦ORGOVYX net product revenue is estimated to be in the range of $24.2-$24.6 million for fiscal third quarter 2021, reflecting 40% sequential volume growth compared to fiscal second quarter 2021, partially offset by a lower net price due to higher gross-to-net discounts. There were no material changes in channel inventory for ORGOVYX over the course of fiscal third quarter 2021.



◦MYFEMBREE net product revenue is estimated to be in the range of $2.3-$2.6 million for fiscal third quarter 2021. New-to-brand prescription (NBRx) share among GnRH antagonists FDA-approved for the treatment of uterine fibroids was 45% in December 2021 compared to 20% in September 2021, reflecting steadily increasing demand for the differentiated clinical profile of MYFEMBREE while growing the class. There were no material changes in channel inventory for MYFEMBREE over the course of fiscal third quarter 2021.

◦RYEQO net product revenue related to product supply and royalties from Gedeon Richter, Myovant’s commercialization partner for RYEQO in Europe and certain other international markets, is estimated to be in the range of $2.3-$2.6 million for fiscal third quarter 2021.

•Pfizer collaboration revenue in fiscal third quarter 2021 was $25.2 million, reflecting the partial recognition of the upfront payment Myovant received from Pfizer in December 2020 and of the regulatory milestone payment that was triggered upon the FDA approval of MYFEMBREE for the management of heavy menstrual bleeding associated with uterine fibroids in May 2021. Pfizer collaboration revenue for fiscal third quarter 2020 was $1.4 million and represents the partial amortization of the upfront payment received from Pfizer.

Unaudited capital resources:

Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Dainippon Pharma Loan Agreement totaled approximately $569.1 million as of December 31, 2021, and consisted of approximately $527.8 million of cash, cash equivalents, and marketable securities and $41.3 million of remaining available borrowing capacity under the Sumitomo Dainippon Pharma Loan Agreement.

Myovant to present at 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022

David Marek, Chief Executive Officer of Myovant Sciences, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investor relations page of Myovant’s website at investors.myovant.com. The webcast will be archived on Myovant’s Investor Relations website following the presentation.

About Relugolix
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces testicular testosterone, a hormone known to stimulate the growth of prostate cancer, and ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis. ORGOVYX® (relugolix 120 mg) was approved in the U.S. by the FDA in December 2020 as the first and only oral GnRH receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix (120 mg) is also under regulatory review in Europe for men with advanced prostate cancer. MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was approved in the U.S. by the FDA in May 2021 as the first and only once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months, and by the European Commission and the Medicines and Healthcare products Regulatory Agency in July 2021 and August 2021, respectively, as RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. In September 2021, the FDA accepted Myovant Sciences’ supplemental New Drug Application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis, setting a target action date of May 6, 2022. MYFEMBREE is also being assessed for contraceptive efficacy in women with endometriosis or uterine fibroids who are 18 to 50 years of age and at risk for pregnancy.
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to two regulatory approvals by the U.S. Food and Drug Administration for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively, as well as regulatory approvals by the European Commission and the Medicines and


Healthcare products Regulatory Agency for women with symptomatic uterine fibroids. Additionally, Myovant has two regulatory submissions under review, a Marketing Authorization Application in advanced prostate cancer and a supplemental New Drug Application in endometriosis-associated pain. Myovant is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant is also developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including the U.S., Japan, China, and the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

About Sumitovant Biopharma Ltd.
Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is the majority shareholder of Myovant, and wholly owns Urovant Sciences, Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences. Sumitovant’s pipeline is comprised of commercialized and investigational medicines across a range of disease areas targeting high unmet need. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. For further information about Sumitovant, please visit https://www.sumitovant.com.

Forward-Looking Statements and Preliminary Financial Results

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this press release, forward-looking statements include, but are not limited to, all statements reflecting Myovant Sciences’ expectations, including but not limited to: Myovant’s expected financial results for the fiscal quarter ended December 31, 2021; the statements regarding Myovant’s aspiration to redefine care for women and for men; the statements regarding ORGOVYX’s and MYFEMBREE’s potential to become standard of care therapies in advanced prostate cancer and uterine fibroids, respectively; and the expectations to expand Myovant’s pipeline by advancing relugolix lifecycle opportunities and pursuing business development.

Myovant Sciences’ forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions, and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements, including the anticipated financial results are preliminary and may be adjusted at a later date following the completion of customary quarterly financial reviews and audit procedures. Myovant Sciences cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could materially affect Myovant Sciences’ operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to, the risks and uncertainties listed in Myovant Sciences’ filings with the United States Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Myovant Sciences’ Quarterly Report on Form 10-Q filed on October 26, 2021, as such risk factors may be amended, supplemented, or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for Myovant Sciences’ management to predict all risk factors, nor can Myovant Sciences assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and, except as required by law, Myovant Sciences undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements.

Furthermore, this press release includes information regarding Myovant Sciences’ preliminary financial results for the third fiscal quarter ended December 31, 2021. Myovant Sciences is currently in the process of finalizing its


financial results for the third fiscal quarter ended December 31, 2021, and the preliminary financial results presented in this press release are based only on preliminary information available to Myovant Sciences as of January 10, 2022. These preliminary financial results should not be viewed as a substitute for audited consolidated financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Myovant Sciences’ preliminary financial results. Myovant Sciences’ independent registered public accounting firm has not audited or reviewed the preliminary financial results included in this press release or expressed any opinion or other form of assurance on such preliminary financial results. In addition, items or events may be identified or occur after the date of this press release due to the completion of operational and financial closing procedures, final audit adjustments and other developments may arise that would require Myovant Sciences to make material adjustments to the preliminary financial results included in this press release. Therefore, the preliminary financial results included in this press release may differ, perhaps materially, from the consolidated financial results that will be reflected in Myovant Sciences’ Quarterly Report on Form 10-Q expected to be filed on January 26, 2022.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

 EX-101.SCH 3 myov-20220110.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 myov-20220110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Country Region Country Region Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type Entity Address, Country Entity Address, Country City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 myov-20220110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 myovant16a.jpg begin 644 myovant16a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover Page
Jan. 10, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 10, 2022
Entity Registrant Name Myovant Sciences Ltd.
Entity File Number 001-37929
Entity Incorporation, State or Country Code D0
Entity Tax Identification Number 98-1343578
Entity Address, Address Line Two Suite 1, 3rd Floor
Entity Address, Address Line One 11-12 St. James’s Square
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code SW1Y 4LB
Country Region 44
City Area Code 207
Local Phone Number 400 3351
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Shares, par value $0.000017727 per share
Trading Symbol MYOV
Security Exchange Name NYSE
Amendment Flag false
Entity Central Index Key 0001679082
XML 8 myov-20220110_htm.xml IDEA: XBRL DOCUMENT 0001679082 2022-01-10 2022-01-10 false 0001679082 8-K 2022-01-10 Myovant Sciences Ltd. 001-37929 D0 98-1343578 Suite 1, 3rd Floor 11-12 St. James’s Square London SW1Y 4LB GB 44 207 400 3351 false false false false Common Shares, par value $0.000017727 per share MYOV NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 119 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://myovant.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports myov-20220110.htm a01102022myovantprx010422e.htm myov-20220110.xsd myov-20220110_lab.xml myov-20220110_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "myov-20220110.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "myov-20220110.htm" ] }, "labelLink": { "local": [ "myov-20220110_lab.xml" ] }, "presentationLink": { "local": [ "myov-20220110_pre.xml" ] }, "schema": { "local": [ "myov-20220110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 119, "memberCustom": 0, "memberStandard": 0, "nsprefix": "myov", "nsuri": "http://myovant.com/20220110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "myov-20220110.htm", "contextRef": "ifc4cbe50f02e4fc9886ca07c96aebf26_D20220110-20220110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://myovant.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "myov-20220110.htm", "contextRef": "ifc4cbe50f02e4fc9886ca07c96aebf26_D20220110-20220110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://myovant.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001679082-22-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001679082-22-000009-xbrl.zip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�<[MSOR1_Y' MF(.=_P%02P$"% ,4 " [2"I4U>BBPDX6 !<<@ '@ M@ $ 83 Q,3 R,#(R;7EO=F%N='!R># Q,#0R,F4N:'1M4$L! A0#% M @ .T@J5.SEG9<6%P E+8 !$ ( !BA8 &UY;W8M,C R M,C Q,3 N:'1M4$L! A0#% @ .T@J5+BR'-D4$L! A0#% @ .T@J5)D2 MFQ()"P 8V4 !4 ( !;3 &UY;W8M,C R,C Q,3!?;&%B M+GAM;%!+ 0(4 Q0 ( #M(*E0K^)6]V+3(P,C(P,3$P7W!R92YX;6Q02P4& 4 !0!0 0 T4( # end